Practical guidelines for the management of biochemotherapy-related toxicity in melanoma

Citation
Ac. Buzaid et M. Atkins, Practical guidelines for the management of biochemotherapy-related toxicity in melanoma, CLIN CANC R, 7(9), 2001, pp. 2611-2619
Citations number
39
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology
Journal title
CLINICAL CANCER RESEARCH
ISSN journal
1078-0432 → ACNP
Volume
7
Issue
9
Year of publication
2001
Pages
2611 - 2619
Database
ISI
SICI code
1078-0432(200109)7:9<2611:PGFTMO>2.0.ZU;2-J
Abstract
The combination of cisplatin-based chemotherapy with interleukin 2 (IL-2) a nd IFN-alpha, referred to as biochemotherapy or chemoimmunotherapy, has sho wn promising antitumor activity in patients with metastatic melanoma. Phase II studies have reported overall response rates ranging from 40 to 60%, wi th durable complete remissions in similar to 10% of the patients. Toxicity, however, is often severe and can be life-threatening if the healthcare tea m is not familiar with toxicity management. In this report, we briefly desc ribe the clinical results of the most effective biochemotherapy regimens an d provide a detailed description and management of the most common toxic ef fects, with emphasis on the concurrent biochemotherapy program initially de veloped at M. D. Anderson Cancer Center and currently being tested in a sli ghtly modified version in two large-scale Intergroup Phase III trials.